← FDA DRUG APPROVALS

FDA BLA · BLA761392

OSPOMYV

denosumab

Sponsor: SAMSUNG BIOEPIS CO LTD

APPLICATION
BLA761392
TYPE
BLA
ORIGINAL APPROVAL
2025-02-13
LATEST ACTION
2025-10-29
ROUTE
SUBCUTANEOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

DENOSUMAB-DSSBPrescription
DENOSUMAB-DSSB 60MG/ML · INJECTABLE · SUBCUTANEOUS
OSPOMYVPrescription
DENOSUMAB-DSSB 60MG/ML · INJECTABLE · SUBCUTANEOUS
DENOSUMAB-DSSBPrescription
DENOSUMAB-DSSB 70MG/ML · INJECTABLE · SUBCUTANEOUS
XBRYKPrescription
DENOSUMAB-DSSB 70MG/ML · INJECTABLE · SUBCUTANEOUS

Approval history

2025-10-29Efficacy · Original · standardLetterAP
2025-02-13UNKNOWN · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →